1. Introduction {#sec1}
===============

The emergence of *Plasmodium falciparum* resistance to antimalarial drugs has been threatening the world\'s malaria control and elimination efforts ([@bib45]). Currently, *P. falciparum* have developed resistance/tolerance to antimalarial drugs chloroquine (CQ) and sulfadoxine-pyrimethamine (SP). Although World Health Organization (WHO) has recommended artemisinin (ART)-based combination therapies (ACTs) as the first-line treatment for uncomplicated *P. falciparum* malaria, *P. falciparum* are becoming insensitive to ART and its derivatives ([@bib15], [@bib43], [@bib4]). At present, virtually all malaria endemic countries in sub-Saharan Africa are adopting either Artemether-Lumefantrine (AL) or Artesunate-Amodiaquine (AS-AQ) as the front-line ACTs. AS-AQ and the ART derivative dihydroartemisinin-piperaquine (DP) are used in Equatorial Guinea (EG) ([@bib7]).

Emerging evidence indicate that *P. falciparum* has been developing the resistance to ART and its derivatives. In Pailin of western Cambodia and other Southeast (SE) Asia area, parasite clearance was delayed following the treatment with ART monotherapy or ACTs ([@bib28], [@bib12], [@bib3], [@bib24], [@bib6]). Our recent study showed the presence of high prevalent mutations in *Pfmdr1* (91.39%) and *Pfcrt* (98.67%) which markers for antimalarial drug resistence in *P. falciparum* clinical isolates on Bioko Island, EG ([@bib21]). It is globally threatening for malaria prevention and treatment ([@bib44], [@bib33]). It is imperative to conduct surveillances to identify areas that are potentially developing drug resistance.

Several molecular markers for antimalarial drug resistance has been identified ([@bib43], [@bib7]). Polymorphisms of the sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase ortholog in *P. falciparum* (*PfSERCA* or *PfATPase6*) has been associated with ART resistance, although the association of SNPs in *PfATPase6* with resistance to ART and the underlying mechanism remains to be confirmed ([@bib17], [@bib2], [@bib27], [@bib10]).

Single-nucleotide polymorphisms (SNPs) in the PF3D7_1343700 kelch propeller (*K13-propeller*) have been identified to be a key causal determinant of ART resistance in SE Asia ([@bib26]). From 2009 to 2015, a series of studies associated with *K13*-propeller has been published particular in Asia ([@bib37], [@bib40], [@bib41]) and WHO Africa region ([@bib9], [@bib30]). In Africa, limited mutations of *K13*-propeller were found in Dakar ([@bib39]), Uganda ([@bib9]), Mali ([@bib30]), and even 12 countries from sub-Saharan Africa ([@bib18]). These studies showed the mutational loci in African countries were different from those of SE Asia ([@bib18]).

Malaria is a serious health problem in EG, especially on Bioko Island. However, whether the ART resistance has been developed on the Bioko Island remains unclear. In this study, we surveyed polymorphisms in *K13-propeller* and *PfATPase6* genes in clinical isolates collected from Bioko Island, EG. Our findings may provide a clue to prevent and treat malaria using ART on Bioko Island, EG.

2. Materials and methods {#sec2}
========================

2.1. Study area {#sec2.1}
---------------

Bioko Island belongs to EG and is located in the Gulf of Guinea, about 100 km off the coast of southern Nigeria and 160 km northwest of continental EG ([Fig. 1](#fig1){ref-type="fig"}). The island has a population of 266 000 inhabitants (2001 census) and a humid tropical environment. The launch of the Bioko Island Malaria Control Project (BIMCP) have had a marked impact on malaria transmission, malaria due to *P. falciparum* is still the major public health problem on the island. The entomological inoculation rates (EIRs) in Bioko Island ranged from 163 to 840, with the outdoor EIRs reaching more than 900 infective mosquito bites yearly and a malaria prevalence of 52% under the age of five years ([@bib31], [@bib32]).

2.2. Samples collection {#sec2.2}
-----------------------

Blood samples (3 ml) were collected from the confirmed malaria cases between September 2013 and March 2014. Approximately 300 μl of blood was aliquoted on 3 MM Whatman® filter paper (Whatman International Ltd., Maidstone, England), and air dried. These filters were then stored individually in Ziplock bags containing silica desiccant beads and kept at −20 °C. These samples were examined using the ICT malaria *P.f.* Cassette Test (ICT Diagnostics, South Africa) and Giemsa-stained thick and thin peripheral blood smear examination with microscope. For quality control, archived malaria positive slides were re-examined and parasitaemia was recorded. The *Plasmodium* spp. was confirmed by *Plasmodium* malaria real time PCR diagnostic kit (Shanghai Liferiver Bio-Tech Corp, China). This study was approved by the ethics committees of Malabo Regional Hospital. The informed consent was obtained from all participated subjects.

2.3. DNA extraction from blood samples {#sec2.3}
--------------------------------------

Genomic DNA (gDNA) was extracted from dried filter blood spots (DBS) by following Chelex-100 extraction procedure described in our previous report ([@bib22]). An 18S-rRNA-based RT-PCR was used to evaluate the quality of *P. falciparum g*DNA.

2.4. Genotyping {#sec2.4}
---------------

Nucleotide and amino-acid sequence of *K13-propeller* and *PfATPase6* used in current study has been reported in PlasmoDB (<http://plasmodb.org>) under Gene ID: PF3D7_1343700 and PF3D7_0106300. In order to illustrate the mutations of *K13*-propeller and *PfATPase6*, one segment of *K13*-propeller gene and one fragment from *PfATPase6* gene were amplified by a nested PCR ([@bib47], [@bib22]), respectively.

The *K13-propeller* and *PfATPase6* genes were amplified by nested PCR using the primers in [Table 1](#tbl1){ref-type="table"}. For first round PCR, 0.5 μl of DNA was amplified with 10 μl 2 × NovoStar Green PCR Mix (1.25 U/μl NovoStar Taq DNA Polymerase, 0.4 mM dNTP Mixture, 2 × PCR Buffer, and 4 mM Mg^2+^), 0.5 μl forward primer (10 μM), 0.5 μl reverse primer (10 μM), and sterile ultrapure water to a final volume of 20 μl. For the second round PCR, 0.5 μl primary PCR products were amplified with 40 μl reaction system, including 20 μl 2 × NovoStar Green PCR Mix, 1.0 μl forward primer (10 μM), 1.0 μl reverse primer (10 μM), and H~2~O (up to 40 μl).

PCR reaction conditions were listed in [Table 1](#tbl1){ref-type="table"}. All PCR products were analyzed using 1.0% agar gel electrophoresis and DNA sequencing using a ABI 3730×L automated sequencer (PE Biosystems, CT, USA). The data was analyzed using the DNAstar (DNASTAR Inc., Madison, WI, USA). The 3D7 *K13*-propeller and *PfATPase6* sequences were used as the references.

2.5. Data analysis {#sec2.5}
------------------

The data was analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL). The mutant and wild-type alleles of the collected clinical samples were used to generate the prevalence of the alleles. A two-tailed *P*-value is less than 0.05 was considered statistically significant. The 95% confidence intervals (95% CI) was calculated as described previously ([@bib22]).

3. Results {#sec3}
==========

3.1. *K13-propeller* polymorphisms {#sec3.1}
----------------------------------

Sequence of a total of 98 (90.74%, 98/108) *K13-propeller* nested PCR products was obtained from 108 (62.79%, 108/172) PCR-positive samples out of the 172 isolates. The *K13-propeller* SNPs were analyzed by comparing with the reference 3D7 strain (PF3D7_1343700) and listed in [Table 2](#tbl2){ref-type="table"}. There was a mutation at position 578. The frequency of A578S was 2.04% (2/98) ([Table 2](#tbl2){ref-type="table"}). No *K13-propeller* mutation was detected at positions 474, 476, 493, 508, 527, 537, 539, 543, 553, 561, 568, 574, and 580. Notably, the C580Y, R539T, and Y493H substitutions that were associated with ART resistance *in vitro* or delayed *P. falciparum* parasite clearance *in vivo* in SE Asia were not detected on the samples from Bioko Island, EG.

3.2. *PfATPase6* polymorphisms {#sec3.2}
------------------------------

Sequence of a total of 139 (91.45%, 139/152) *PfATPase6* nested PCR products was obtained from 152 (88.37%, 152/172) PCR-positive samples out of the 172 isolates. The *PfATPase6* SNPs were analyzed by comparing with the reference 3D7 strain (PF3D7_0106300) and listed in [Table 2](#tbl2){ref-type="table"}. The *PfATPase6* SNPs were found at positions N569K and A630S with the mutation prevalence of 11 (7.91%, 11/139), and 2 (1.44%, 2/139), respectively ([Table 2](#tbl2){ref-type="table"}). In addition, a sample with the mixed type at position I723V was also discovered with the mutation prevalence of 1 (0.72%, 1/139) ([Table 2](#tbl2){ref-type="table"}). The remaining mutations of K561N, A623E, G639D, N683K, and S769N, all the investigated samples verified the wild-type genotype. Notably, the S769N substitution that was connected with ART resistance was not found from these samples.

4. Discussion {#sec4}
=============

For EG, both the AS-AQ and DP are considered as the front-line treatment for uncomplicated *falciparum* malaria. It is essential to understand molecular mutation profiles of *P. falciparum* parasite for ART resistance and use this initial information for molecular assessment under antimalarial drug pressure. In current study, we only find limited mutation of *K13-propeller* and low frequency of *PfATPase6* mutation of the clinical isolates from Bioko Island, EG. It is the initial report focusing on the molecular markers of *K13-propeller* and *PfATPase6* for ART resistance on this Island.

The ART resistance considers as a major risk to public health, with the most rigorous potential effect in Sub-Saharan Africa, where the burden is seriously. Furthermore, the international investments and domestic investments, the prevention and elimination system for malaria are also insufficient in the region. The hazard of ART-resistant parasites scattering from western Cambodia to the Greater Mekong Subregion and then to Africa particularly Sub-Saharan Africa, as happened previously with CQ and SP-resistant parasites ([@bib44], [@bib33]), is worrying ([@bib5]). A significant action of the WHO Global Plan for Artemisinin Resistance Containment is to increase monitoring and molecular surveillance ([@bib36]). However, it is difficult to evaluate how long or when ART resistance mutations will appear in Africa including EG, and molecular detection can offer a profile to speedily discover for the appearance or importation of resistance alleles ([@bib38]). In SE Asia, the mutations of *K13-propeller* are found in both western Cambodia ([@bib5], [@bib34]) and Bangladesh ([@bib25]). In Africa, only limited polymorphisms of *K13-propeller* are detected ([@bib8], [@bib38], [@bib39]). However, the *K13-propeller* polymorphism in returned migrant workers from Ghana is found in Shanglin of China ([@bib13]). Thus, it is very necessary to strengthen *Plasmodium* parasites genotypic resistance surveillance with *K13-propeller* polymorphism. If there is no sufficient attention to long-term survey, it will be a disaster for human health.

The survey of *P. falciparum K13-propeller* polymorphisms primarily explore a diversity of mutations across on Bioko Island, EG. Limited polymorphisms associated with ART resistance from SE Asia are observed in the clinical isolates. Recent study reports that the SNP mutations at Y493H, I543T, R539T, and C580Y are powerfully connected with prolonging *P. falciparum* parasite survival time *ex vivo*; ART resistance *in vitro* has to be M476I mutation-related, which indicates that mutations of *K13-propeller* can generate an ART-resistance phenotype *in vitro* with genetic background from African parasite ([@bib5]). Although the five mutations play crucial role during ART-resistance to *P. falciparum* parasite *in vitro* and *in vivo*, we observe none of these mutations in the survey parasite samples. Only one *K13-propeller* A578S mutation (2.04%, 2/98) that previously reported from Cambodia is discovered in the six *K13-propeller* blades. This mutation is previously found in 0.75% (1/133) of the isolates tested in Uganda and also presents in parasites from DRC, Gabon, Ghana, Kenya, and Mali ([@bib5], [@bib8], [@bib18]). Although the prevalence of A578S mutant allele from Bioko Island is lower than Kenya at 2.7%, it is still higher in parasites compared to 1% in the other four countries of Sub-Saharan Africa. This unusual polymorphism also merits further characterization ([@bib38]). Mutations of A481V, G533C and A578S are confirmed and adjacent to the Y493H, R539T, C580Y mutation, and propose the mutations may have a significant effect on three-dimensional structure of the *K13-propeller*. Furthermore, the mutations of S522S, Y558H report in Ugandan children and A557S in Congo have not detected on Bioko Island ([@bib8], [@bib38]). The V520A mutation identified from West, Central and East Africa is also not found on the Island, Dakar and Uganda ([@bib35], [@bib38]). These results encourage and suggest ART resistance is not yet established in Africa particular on Bioko Island, EG. Although none of the mutations associated with ART resistance in SE Asia are detected in Africa ([@bib8], [@bib38]), numerous novel *K13-propeller* coding substitutions bothers in the whole continent of Africa. The phenotypes of these coding polymorphisms remain unclear and will require further characterization to better characterize the clinical impact on ART resistance in Africa. Further analysis of phylogenetic tree or haplotype network is needed to trace the origin of the *K13-propeller* mutations and to determine whether the ART resistance is widely spreaded from SE Asia or emerged independently in Bioko Island, EG ([@bib29]).

Polymorphisms evaluation of *PfATPase6* in Africa have occurred rarely ([@bib27], [@bib20], [@bib14], [@bib23], [@bib19], [@bib46]). The current study initial describes for the *PfATPase6* polymorphism on Bioko Island, EG. Among the three different observed mutations, only one, the N569K mutation, is relatively frequent 7.91% of isolates. The previous studies have also found a high prevalence of this mutation in Zanzibar (36%) and Tanzania (29%) ([@bib11]), Niger (17.2%) ([@bib16]). The *PfATPase6* S769N mutation is absent in all Bioko samples and consistent with previous results in Africa countries ([@bib27], [@bib20], [@bib14], [@bib23], [@bib19], [@bib46]) and South America ([@bib1]). It demonstrates that the Africa and South America share the similar molecular pattern of *PfATPase6* for ART resistance.

5. Conclusions {#sec5}
==============

The present study shows that the low prevalence polymorphism mutations of *PfATPase6* and limited mutations of *K13-propeller*, potentially associated with ART resistance, are obviously observed on Bioko Island, EG. Continuous molecular surveillance with *K13-*propeller gene as ART resistance marker is exceedingly recommended on Bioko Island, EG. Furthermore, it might be helpful for developing and updating guidance for the use of ACTs.
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###### 

Primers and PCR conditions for genotyping.

  Gene                Primer                         Sequence (5′--3′)   Size (bp)                                                                                                            Mutation
  ------------------- ------------------------------ ------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  *K13-propeller*     **1st round PCR**                                                                                                                                                       
  K13-1               CGGAGTGACCAAATCTGGGA           2097                                                                                                                                     95 °C 3 min; followed by 30 cycles (95 °C 30 s, 55 °C 30 s, 72 °C 30 s); 72 °C 5 min; then store 12 °C.
  K13-4               GGGAATCTGGTGGTAACAGC                                                                                                                                                    
  **2nd round PCR**                                                                                                                                                                           
  PfK13_inF2          TCAACAATGCTGGCGTATGTG          501                 T474I, M476I, A481V, Y493H, T508N, P527T, G533S, N537I, R539T, I543T, P553L, R561H, V568G, P574L, A578S, and C580Y   95 °C 3 min; followed by 30 cycles (95 °C 30 s, 55 °C 30 s, 72 °C 30 s); 72 °C 5 min; then store 12 °C.
  PfK13_inR2          TGATTAAG GTAATTAAAAGCTGCTCC                                                                                                                                             
  *PfATPase6*         **1st round PCR**                                                                                                                                                       
  PfATPase6-N1F       AATATTGTTATTCAGAATATGATTATAA   896                                                                                                                                      95 °C 3 min; followed by 30 cycles (95 °C 30 s, 55 °C 30 s, 72 °C 50 s); 72 °C 5 min; then store 12 °C.
  PfATPase6-N1R       TGGATCAATAATACCTAATCCACCTA                                                                                                                                              
  **2nd round PCR**                                                                                                                                                                           
  PfATPase6-N2F       AGCAAATATTTTCTGTAACGATAATA     798                 K561N, N569K, A623E, A630S, G639D, N683K, I723V, and S769N                                                           95 °C 3 min; followed by 30 cycles (95 °C 30 s, 58 °C 30 s, 72 °C 45 s); 72 °C 5 min; then store 12 °C.
  PfATPase6-N2R       TGTTCTAATTTATAATAATCATCTGT                                                                                                                                              

###### 

*K13-propeller and PfATPase6* polymorphisms in *Plasmodium falciparum* isolates on Bioko Island, Equatorial Guinea.

  Gene              Reference   No. of isolates                                                                          
  ----------------- ----------- ----------------- --------- --------- --------- ------ ----- ----- --------------------- ---------------------
  *K13-propeller*   578         A                 **g**ct   S         **T**ct   1732   108   98    2                     2.04, −0.76 to 4.84
  *PfATPase6*       569         N                 aa**a**   K         aa**T**   1707   152   139   11                    7.91, 3.42 to 12.4
  630               A           **g**ct           S         **T**ct   1888      152    139   2     1.44, −0.54 to 3.42   
  723               I           **a**ta           V         **G**ta   2167      152    139   1     0.72, −0.69 to 2.13   

Bold, AA and No. represent single nucleotide polymorphism mutation, amino acid residue and number.
